According to a report in Live Mint which quoted data from VCCEdge, outbound mergers and acquisitions in the healthcare sector in India were worth $1.5 billion in 2015 as against $251 million in 2014.
Outbound Acquisitions | ||
| Acquirer | Acquiree | Deal Size |
| Lupin, India | Gavis Pharmaceuticals, U.S. | $880 million |
| Cipla, India | InvaGen and Exelan, U.S. | $550 million |
| Strides Arcolab, India | Aspen Pharmacare, Australia | $287 million |
Inbound deals also more than doubled to $999 million in 2015 from $430 million in 2014.
Inbound Acquisitions | ||
| Acquirer | Acquiree | Deal Size |
| Mylan, U.S. | Famy-Care, India | $800 million |
| Recipharm AB, Sweden | Nitin Life Sciences, India | $100 million |
| IHH Healthcare Bhd, Malaysia | Ravindranath GE Medical, India | $200 million |
| IHH Healthcare Bhd, Malaysia | Continental Hospitals, India | $45.4 million |
| Temasek Holdings, Singapore | Medanta, India (18% stake) | undisclosed |
| Bionpharma, U.S. | Banner Life Sciences, India (25 products that generate $70 million annually) | undisclosed |
